Comparative Pharmacology
Head-to-head clinical analysis: ESTROVIS versus NORGESTREL AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROVIS versus NORGESTREL AND ETHINYL ESTRADIOL.
ESTROVIS vs NORGESTREL AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrovis (estropipate) acts by binding to estrogen receptors (ERα and ERβ), leading to activation of estrogen-responsive genes. It increases hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins, and suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
Norgestrel is a progestogen that suppresses gonadotropin secretion, primarily LH, inhibiting ovulation and altering cervical mucus to impede sperm penetration. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides negative feedback on gonadotropin release, contributing to contraceptive efficacy.
1 mg orally once daily, continuous dosing cycle (no placebo week).
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily, taken at the same time each day.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours (mean 15 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 3-5 days.
Norgestrel: terminal half-life ~45 hours (range 24–50 h), supporting once-daily dosing; Ethinyl estradiol: terminal half-life ~17 hours (range 10–24 h).
Renal: 60-70% as glucuronide and sulfate conjugates; Fecal/biliary: 20-30% as conjugated metabolites.
Norgestrel: 45% renal, 32% fecal as metabolites; Ethinyl estradiol: 40% renal, 60% fecal as glucuronide and sulfate conjugates.
Category C
Category D/X
Estrogen
Estrogen